NCT04618367
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +10 more
- Locations
-
- Second Affiliated Hospital of Guangzhou Medical University Guangzhou, Guangdong, China
Clinical trial condition
Sintilimab
Explore clinical trials studying Sintilimab. Study availability and eligibility vary by location and protocol.
14 public trials
8 recruiting studies
Sintilimab trial results
NCT03936452
- Conditions
- Anlotinib, Early Stage, Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, +5 more
- Locations
-
- Sun Yat-Sen University Cancer Center Guangzhou, Guangdong, China
Active, Not Recruiting
Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC
NCT05400070
- Conditions
- Anlotinib, Chemotherapy, Lung Cancer, +8 more
- Locations
-
- Tangdu Hospital, the Air Force Military University Xi'an, China
Active, Not Recruiting
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
NCT06342167
- Conditions
- Concurrent Chemoradiotherapy, Immunonutrition, Locally Advanced Esophageal Squamous Cell Carcinoma, +2 more
- Locations
-
- Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing, Beijing Municipality, China
- Department of Radiation Oncology，Clinical Oncology School of Fujian Medical University，Fujian Cancer Hospital Fujian, China
- Department of Oncology, Affiliated Hospital, Hebei University of Engineering Handan, Hebei, China
- Department 1st of Radiation Oncology, Anyang Tumor Hospital Anyang, Henan, China